Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3912]

Positive data for the use of radioligand therapy in first-line neuroendocrine...

Dr Simron Singh - University of Toronto, Toronto, Canada

Positive data for the use of radioligand therapy in first-line neuroendocrine cancers ( Dr Simron Singh - University of Toronto, Toronto, Canada )

Perspectives on advance care planning for advanced cancer in the Philippines

Dr Sachiko Estreller - Cordillera Hospital of the Divine Grace, Benguet...

Perspectives on advance care planning for advanced cancer in the Philippines ( Dr Sachiko Estreller - Cordillera Hospital of the Divine Grace, Benguet, Philippines )

Durable responses in aRCC, how do we optimise treatment?

Prof Roberto Iacovelli and Prof Viktor Grünwald

Durable responses in aRCC, how do we optimise treatment? ( Prof Roberto Iacovelli and Prof Viktor Grünwald )

The combination of regorafenib, nivolumab and SCRT shows promising efficacy as...

Dr Francesco Sclafani - Institut Jules Bordet, Brussels, Belgium

The combination of regorafenib, nivolumab and SCRT shows promising efficacy as neoadjuvant therapy for locally advanced RC ( Dr Francesco Sclafani - Institut Jules Bordet, Brussels, Belgium )

Trifluridine/tipiracil followed by regorafenib can be an effective treatment...

Prof Michel Ducreux - Gustave Roussy Cancer Centre, Paris, France

Trifluridine/tipiracil followed by regorafenib can be an effective treatment sequence in pretreated mCRC ( Prof Michel Ducreux - Gustave Roussy Cancer Centre, Paris, France )

Preview: World Cancer Congress 2024

Union for International Cancer Control

Preview: World Cancer Congress 2024 ( Union for International Cancer Control )

Durvalumab, gemcitabine and cisplatin continue to show clinically meaningful...

Dr Do-Youn Oh - Seoul National University Hospital, Seoul, Korea

Durvalumab, gemcitabine and cisplatin continue to show clinically meaningful long-term survival in biliary tract cancer patients ( Dr Do-Youn Oh - Seoul National University Hospital, Seoul, Korea )

Pembrolizumab combined with xelox and bevacizumab shows higher efficacy than...

Prof David Tougeron - Poitiers University Hospital, Poitiers, France

Pembrolizumab combined with xelox and bevacizumab shows higher efficacy than standard therapeutic regimen in mCRC ( Prof David Tougeron - Poitiers University Hospital, Poitiers, France )

Paclitaxel and ramucirumab switch maintenance therapy prolongs survival in HER2...

Dr Giovanni Randon - The National Cancer Institute of Milan, Milano, Italy

Paclitaxel and ramucirumab switch maintenance therapy prolongs survival in HER2-negative advanced GEJ cancer ( Dr Giovanni Randon - The National Cancer Institute of Milan, Milano, Italy )

Administering systemic chemotherapy improves survival for patients with...

Dr Giacomo Bregni - Francis Crick Institute, London, England

Administering systemic chemotherapy improves survival for patients with resectable CRCLM ( Dr Giacomo Bregni - Francis Crick Institute, London, England )

Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse...

Dr Jeremy Abramson - Mass General Cancer Center, Boston, USA

$Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma ( Dr Jeremy Abramson - Mass General Cancer Center, Boston, USA )$

TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic...

Dr Consuelo Bertossi - University Hospital of Ulm, Ulm, Germany

TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia ( Dr Consuelo Bertossi - University Hospital of Ulm, Ulm, Germany )

More from ecancer